MX2025009067A - Metodos para cuantificar la il-33 - Google Patents
Metodos para cuantificar la il-33Info
- Publication number
- MX2025009067A MX2025009067A MX2025009067A MX2025009067A MX2025009067A MX 2025009067 A MX2025009067 A MX 2025009067A MX 2025009067 A MX2025009067 A MX 2025009067A MX 2025009067 A MX2025009067 A MX 2025009067A MX 2025009067 A MX2025009067 A MX 2025009067A
- Authority
- MX
- Mexico
- Prior art keywords
- sample
- soluble
- complexes
- blocking agent
- assay
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Se proporcionan métodos y composiciones para detectar y cuantificar citocinas. Los ensayos descritos tienen menor interferencia del ensayo con respecto a ensayos disponibles en el mercado y/o un ensayo de control. La interferencia puede ser dependiente de la citocina, independiente de la citocina o ambos. Una modalidad proporciona un inmunoensayo de IL-33 que reduce la interferencia del ensayo provocada por moléculas de unión a IL-33 solubles presentes en la muestra. Las moléculas de unión a IL 33 solubles incluyen, de modo no taxativo, anticuerpos anti-IL-33, receptor ST2 soluble y componentes de suero. En algunas modalidades se agrega un agente de bloqueo a la muestra para reducir, inhibir o bloquear los complejos de IL-33 en la muestra para evitar la reformación después de la disociación de ácido de los complejos de IL-33 en la muestra. En una modalidad, el agente de bloqueo y el reactivo de detección no compiten por la unión a IL-33.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655887P | 2018-04-11 | 2018-04-11 | |
| PCT/US2019/026699 WO2019199910A1 (en) | 2018-04-11 | 2019-04-10 | Methods for quantifying il-33 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025009067A true MX2025009067A (es) | 2025-09-02 |
Family
ID=66287025
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010714A MX2020010714A (es) | 2018-04-11 | 2019-04-10 | Metodos para cuantificar la il-33. |
| MX2025009067A MX2025009067A (es) | 2018-04-11 | 2020-10-09 | Metodos para cuantificar la il-33 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010714A MX2020010714A (es) | 2018-04-11 | 2019-04-10 | Metodos para cuantificar la il-33. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12092634B2 (es) |
| EP (1) | EP3775898A1 (es) |
| JP (2) | JP7328250B2 (es) |
| KR (1) | KR102759111B1 (es) |
| CN (2) | CN111954814B (es) |
| AU (2) | AU2019251973B2 (es) |
| BR (1) | BR112020020686A2 (es) |
| CA (1) | CA3095786A1 (es) |
| EA (1) | EA202092454A1 (es) |
| IL (3) | IL277890B2 (es) |
| MX (2) | MX2020010714A (es) |
| MY (1) | MY202604A (es) |
| SG (1) | SG11202009590WA (es) |
| WO (1) | WO2019199910A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115343480A (zh) * | 2022-06-28 | 2022-11-15 | 浙江理工大学绍兴生物医药研究院有限公司 | 一种检测il-33的诊断试剂盒及制备和检测方法 |
| US20240027432A1 (en) * | 2022-07-13 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Mild acid immunoassays for detection of analytes |
| CN117054663A (zh) * | 2023-08-01 | 2023-11-14 | 湖南卓润生物科技有限公司 | 检测可溶性生长刺激表达基因2蛋白的试剂盒 |
| WO2025239335A1 (ja) * | 2024-05-13 | 2025-11-20 | デンカ株式会社 | 被検物質の検出方法及びそのためのキット |
| CN120121849A (zh) * | 2025-04-29 | 2025-06-10 | 美康生物科技股份有限公司 | 一种用于定量检测可溶性生长刺激表达基因2蛋白的试剂盒及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| KR20070012838A (ko) | 2004-05-19 | 2007-01-29 | 가부시끼가이샤 센단세메이가가꾸겐큐죠 | Ｂ형간염 바이러스의 검출방법 |
| US8147817B2 (en) | 2006-05-04 | 2012-04-03 | The Brigham And Women's Hospital, Inc. | IL-33 in the treatment and diagnosis of diseases and disorders |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| WO2008033073A1 (en) * | 2006-09-14 | 2008-03-20 | Ge Healthcare Bio-Sciences Ab | A method of determining analyte concentration |
| EP2475388B1 (en) | 2009-09-10 | 2017-11-08 | Merck Sharp & Dohme Corp. | Use of il-33 antagonists to treat fibrotic disease |
| SI2564202T1 (sl) * | 2010-04-29 | 2015-12-31 | Theradiag Sa | Metode za odkrivanje protiteles proti zdravilu |
| EP2490024A1 (en) * | 2010-12-22 | 2012-08-22 | Proteomika, S.L. | Method to optimize the treatment of patients with biological drugs |
| TW201238976A (en) | 2011-02-23 | 2012-10-01 | Hoffmann La Roche | Antibodies against human IL33R and uses thereof |
| US9212227B2 (en) | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| MX364591B (es) | 2013-03-15 | 2019-05-02 | Regeneron Pharma | Antagonistas de il-33 y usos de estos. |
| US10261094B2 (en) * | 2013-10-31 | 2019-04-16 | Regeneron Pharmaceuticals, Inc. | Competitive ligand binding assay for detecting neutralizing antibodies |
| TWI563003B (en) | 2013-12-26 | 2016-12-21 | Mitsubishi Tanabe Pharma Corp | Human anti-il-33 neutralization monoclonal antibody |
| EP3092253B1 (en) | 2014-01-10 | 2021-03-17 | AnaptysBio, Inc. | Antibodies directed against interleukin-33 (il-33) |
| RS58212B1 (sr) * | 2014-02-11 | 2019-03-29 | Genzyme Corp | Testovi za otkrivanje prisustva ili količine anti-lek antitela |
| NO2785538T3 (es) | 2014-05-07 | 2018-08-04 | ||
| CA2960297A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| CN107109494B (zh) | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Il-33介导型疾病的治疗方法和诊断方法 |
| HUE053097T2 (hu) | 2015-03-31 | 2021-06-28 | Medimmune Ltd | Új IL33 forma, IL33 mutáltatott formái, ellenanyagok, vizsgálati eljárások és eljárások azok alkalmazására |
| JP6889160B2 (ja) * | 2015-12-16 | 2021-06-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ３段階酸解離酵素結合免疫吸着（ｔａｄｅｌｉｓ）アッセイ法 |
| AU2017257330A1 (en) | 2016-04-27 | 2018-10-18 | Pfizer Inc. | Anti-IL-33 antibodies, compositions, methods and uses thereof |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| CN107422131A (zh) * | 2017-07-28 | 2017-12-01 | 江苏龙维生物科技有限公司 | 可溶性st2的检测方法及检测试剂盒 |
-
2018
- 2018-04-10 IL IL277890A patent/IL277890B2/en unknown
-
2019
- 2019-04-10 CN CN201980025050.6A patent/CN111954814B/zh active Active
- 2019-04-10 BR BR112020020686-5A patent/BR112020020686A2/pt unknown
- 2019-04-10 SG SG11202009590WA patent/SG11202009590WA/en unknown
- 2019-04-10 KR KR1020207030235A patent/KR102759111B1/ko active Active
- 2019-04-10 MY MYPI2020005073A patent/MY202604A/en unknown
- 2019-04-10 CN CN202310628426.0A patent/CN116660522A/zh active Pending
- 2019-04-10 JP JP2020555412A patent/JP7328250B2/ja active Active
- 2019-04-10 MX MX2020010714A patent/MX2020010714A/es unknown
- 2019-04-10 WO PCT/US2019/026699 patent/WO2019199910A1/en not_active Ceased
- 2019-04-10 EP EP19719730.4A patent/EP3775898A1/en active Pending
- 2019-04-10 EA EA202092454A patent/EA202092454A1/ru unknown
- 2019-04-10 AU AU2019251973A patent/AU2019251973B2/en active Active
- 2019-04-10 CA CA3095786A patent/CA3095786A1/en active Pending
- 2019-04-10 US US17/046,200 patent/US12092634B2/en active Active
-
2020
- 2020-10-09 MX MX2025009067A patent/MX2025009067A/es unknown
-
2023
- 2023-08-03 JP JP2023126792A patent/JP7586984B2/ja active Active
- 2023-09-27 IL IL307286A patent/IL307286B1/en unknown
-
2024
- 2024-08-14 US US18/805,236 patent/US20240402158A1/en active Pending
-
2025
- 2025-09-02 AU AU2025226667A patent/AU2025226667A1/en active Pending
- 2025-10-15 IL IL323993A patent/IL323993A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL277890B1 (en) | 2023-11-01 |
| US20240402158A1 (en) | 2024-12-05 |
| IL307286A (en) | 2023-11-01 |
| BR112020020686A2 (pt) | 2021-01-19 |
| JP2021521431A (ja) | 2021-08-26 |
| IL307286B1 (en) | 2025-11-01 |
| US20210033600A1 (en) | 2021-02-04 |
| JP7586984B2 (ja) | 2024-11-19 |
| CN116660522A (zh) | 2023-08-29 |
| CN111954814B (zh) | 2023-06-16 |
| CN111954814A (zh) | 2020-11-17 |
| IL277890A (en) | 2020-11-30 |
| AU2019251973B2 (en) | 2025-06-26 |
| AU2025226667A1 (en) | 2025-09-18 |
| KR20200142014A (ko) | 2020-12-21 |
| JP7328250B2 (ja) | 2023-08-16 |
| KR102759111B1 (ko) | 2025-01-24 |
| AU2019251973A1 (en) | 2020-10-29 |
| IL277890B (en) | 2020-11-30 |
| MX2020010714A (es) | 2021-01-08 |
| WO2019199910A1 (en) | 2019-10-17 |
| EP3775898A1 (en) | 2021-02-17 |
| CA3095786A1 (en) | 2019-10-17 |
| MY202604A (en) | 2024-05-09 |
| SG11202009590WA (en) | 2020-10-29 |
| US12092634B2 (en) | 2024-09-17 |
| IL323993A (en) | 2025-12-01 |
| IL277890B2 (en) | 2024-03-01 |
| JP2023145692A (ja) | 2023-10-11 |
| EA202092454A1 (ru) | 2021-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025009067A (es) | Metodos para cuantificar la il-33 | |
| JP2019535015A5 (es) | ||
| JP2019530875A5 (es) | ||
| CN105765386B (zh) | 用于检测中和抗体的竞争性配体结合测定法 | |
| Fredolini et al. | Immunocapture strategies in translational proteomics | |
| EA202190237A1 (ru) | Способы уменьшения мешающего влияния мишени лекарственного средства в иммунологическом анализе на антитела к лекарственному средству (ada) | |
| Zhang et al. | Enhanced ELISA using a handheld pH meter and enzyme-coated microparticles for the portable, sensitive detection of proteins | |
| NZ592552A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| RU2017144232A (ru) | Пары биологических маркеров для предсказания преждевременных родов | |
| WO2013132347A3 (en) | Improved elisa immunoassay for calprotectin | |
| ATE449337T1 (de) | Assay | |
| MX2021013519A (es) | Ensayos de union de ligandos competitivos mejorados. | |
| GB2548978A (en) | Chemiluminescence protein chip, kit and method for detecting seroglycoid fucose index | |
| FI4215621T3 (fi) | Nukleosomimodifikaatioiden kvantifiointi kemiallisesti määriteltyjä rekombinanttinukleosomeja käyttämällä | |
| Dixit et al. | Evaluation of apparent non-specific protein loss due to adsorption on sample tube surfaces and/or altered immunogenicity | |
| BR112014020513A2 (pt) | Métodos e sistemas para amplificação de sinal de bioensaios | |
| DE502005005132D1 (de) | Verfahren zur erhöhung des dynamischen messbereichs von auf spezifischen bindereaktionen basierenden, insbesondere immunologischen testelementen | |
| BR112022021039A2 (pt) | Ensaio de anticorpo neutralizante para proteínas terapêuticas | |
| US20230266327A1 (en) | Use of a fibrinogen capture agent to detect a ciz1 b-variant | |
| Horlock | Enzyme-linked immunosorbent assay (ELISA) | |
| EP2815238A2 (en) | A process for detection and optional quantification of an analyte | |
| ZA202108085B (en) | Novel ligand assays | |
| WO2021239700A3 (de) | Bestimmung krankheitsspezifischer protein-aggregate in stuhlproben | |
| Yang et al. | A biotin–streptavidin signal amplification strategy for a highly sensitive chemiluminescent immunoassay for chicken interferon-γ | |
| CA2549066A1 (en) | Diagnosing acute coronary syndrome by measuring levels of free papp-a |